Global Prevalence of COVID-19-Associated Mucormycosis (CAM):
Living Systematic Review and Meta-Analysis

J 2021

Global Prevalence of COVID-19-Associated Mucormycosis (CAM): Living Systematic Review and Meta-Analysis

HUSSAIN, Mohammad Salman, Abanoub RIAD, Ambrish SINGH, Jitka KLUGAROVÁ, Benny ANTONY et. al.

Basic information

Original name

Global Prevalence of COVID-19-Associated Mucormycosis (CAM): Living Systematic Review and Meta-Analysis

Authors

HUSSAIN, Mohammad Salman (356 India, guarantor, belonging to the institution), Abanoub RIAD (818 Egypt, belonging to the institution), Ambrish SINGH, Jitka KLUGAROVÁ (203 Czech Republic, belonging to the institution), Benny ANTONY, Hasanul BANNA and Miloslav KLUGAR (203 Czech Republic, belonging to the institution)

Edition

Journal of Fungi, Basel, MDPI, 2021, 2309-608X

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

10612 Mycology

Country of publisher

Switzerland

Confidentiality degree

není předmětem státního či obchodního tajemství

References:

URL

Impact factor

Impact factor: 5.724

RIV identification code

RIV/00216224:14110/21:00122984

Organization unit

Faculty of Medicine

DOI

http://dx.doi.org/10.3390/jof7110985

UT WoS

000723730200001

Keywords in English

coinfection; COVID-19; epidemiology; meta-analysis; mucormycosis; mycoses; prevalence; risk factors; systematic review

Abstract

V originále

Mucormycosis, a secondary fungal infection, gained much attention in the ongoing COVID-19 pandemic. This deadly infection has a high all-cause mortality rate and imposes a significant economic, epidemiological, and humanistic burden on the patients and healthcare system. Evidence from the published epidemiological studies showed the varying prevalence of COVID-19-associated mucormycosis (CAM). This study aims to compute the pooled prevalence of CAM and other associated clinical outcomes. MEDLINE, Embase, Cochrane COVID-19 Study Register, and WHO COVID-19 databases were scanned to retrieve the relevant articles until August 2021. All studies reporting the prevalence of mucormycosis among COVID-19 patients were eligible for inclusion. Two investigators independently screened the articles against the selection criteria, extracted the data, and performed the quality assessment using the JBI tool. The pooled prevalence of CAM was the primary outcome, and the pooled prevalence of diabetes, steroid exposure, and the mortality rate were the secondary outcomes of interest. Comprehensive Meta-Analysis software version 2 was used for performing the meta-analysis. This meta-analysis comprised six studies with a pooled sample size of 52,916 COVID-19 patients with a mean age of 62.12 ± 9.69 years. The mean duration of mucormycosis onset was 14.59 ± 6.88 days after the COVID-19 diagnosis. The pooled prevalence of CAM (seven cases per 1000 patients) was 50 times higher than the highest recorded background of mucormycosis (0.14 cases per 1000 patients). A high mortality rate was found among CAM patients with a pooled prevalence rate of 29.6% (95% CI: 17.2–45.9%). Optimal glycemic control and the judicious use of steroids should be the approach for tackling rising CAM cases.

Links

EF18_053/0016952, research and development project

Name: Postdoc2MUNI

LTC20031, research and development project

Name: Towards an International Network for Evidence-based Research in Clinical Health Research in the Czech Republic

Investor: Ministry of Education, Youth and Sports of the CR, INTER-COST

MUNI/A/1608/2020, interní kód MU

Name: Prohlubování znalostí v oblasti zdravotních rizik a benefitů výživy, prostředí a životního stylu III

Investor: Masaryk University

MUNI/IGA/1543/2020, interní kód MU

Name: Evidence-based Practice of Healthcare Professionals and Students in the Czech Republic (Acronym: Evidence-Based Practice in Czechia)

Investor: Masaryk University

Citovat

HUSSAIN, Mohammad Salman, Abanoub RIAD, Ambrish SINGH, Jitka KLUGAROVÁ, Benny ANTONY, Hasanul BANNA and Miloslav KLUGAR. Global Prevalence of COVID-19-Associated Mucormycosis (CAM): Living Systematic Review and Meta-Analysis. Journal of Fungi. Basel: MDPI, 2021, vol. 7, No 11, p. 1-16. ISSN 2309-608X. Available from: https://dx.doi.org/10.3390/jof7110985.

@article{1805081,
   author = {Hussain, Mohammad Salman and Riad, Abanoub and Singh, Ambrish and Klugarová, Jitka and Antony, Benny and Banna, Hasanul and Klugar, Miloslav},
   article_location = {Basel},
   article_number = {11},
   doi = {http://dx.doi.org/10.3390/jof7110985},
   keywords = {coinfection; COVID-19; epidemiology; meta-analysis; mucormycosis; mycoses; prevalence; risk factors; systematic review},
   language = {eng},
   issn = {2309-608X},
   journal = {Journal of Fungi},
   title = {Global Prevalence of COVID-19-Associated Mucormycosis (CAM): Living Systematic Review and Meta-Analysis},
   url = {https://www.mdpi.com/2309-608X/7/11/985},
   volume = {7},
   year = {2021}
}

TY  - JOUR
ID  - 1805081
AU  - Hussain, Mohammad Salman - Riad, Abanoub - Singh, Ambrish - Klugarová, Jitka - Antony, Benny - Banna, Hasanul - Klugar, Miloslav
PY  - 2021
TI  - Global Prevalence of COVID-19-Associated Mucormycosis (CAM): Living Systematic Review and Meta-Analysis
JF  - Journal of Fungi
VL  - 7
IS  - 11
SP  - 1-16
EP  - 1-16
PB  - MDPI
SN  - 2309608X
KW  - coinfection
KW  - COVID-19
KW  - epidemiology
KW  - meta-analysis
KW  - mucormycosis
KW  - mycoses
KW  - prevalence
KW  - risk factors
KW  - systematic review
UR  - https://www.mdpi.com/2309-608X/7/11/985
N2  - Mucormycosis, a secondary fungal infection, gained much attention in the ongoing COVID-19 pandemic. This deadly infection has a high all-cause mortality rate and imposes a significant economic, epidemiological, and humanistic burden on the patients and healthcare system. Evidence from the published epidemiological studies showed the varying prevalence of COVID-19-associated mucormycosis (CAM). This study aims to compute the pooled prevalence of CAM and other associated clinical outcomes. MEDLINE, Embase, Cochrane COVID-19 Study Register, and WHO COVID-19 databases were scanned to retrieve the relevant articles until August 2021. All studies reporting the prevalence of mucormycosis among COVID-19 patients were eligible for inclusion. Two investigators independently screened the articles against the selection criteria, extracted the data, and performed the quality assessment using the JBI tool. The pooled prevalence of CAM was the primary outcome, and the pooled prevalence of diabetes, steroid exposure, and the mortality rate were the secondary outcomes of interest. Comprehensive Meta-Analysis software version 2 was used for performing the meta-analysis. This meta-analysis comprised six studies with a pooled sample size of 52,916 COVID-19 patients with a mean age of 62.12 ± 9.69 years. The mean duration of mucormycosis onset was 14.59 ± 6.88 days after the COVID-19 diagnosis. The pooled prevalence of CAM (seven cases per 1000 patients) was 50 times higher than the highest recorded background of mucormycosis (0.14 cases per 1000 patients). A high mortality rate was found among CAM patients with a pooled prevalence rate of 29.6% (95% CI: 17.2–45.9%). Optimal glycemic control and the judicious use of steroids should be the approach for tackling rising CAM cases.
ER  -

HUSSAIN, Mohammad Salman, Abanoub RIAD, Ambrish SINGH, Jitka KLUGAROVÁ, Benny ANTONY, Hasanul BANNA and Miloslav KLUGAR. Global Prevalence of COVID-19-Associated Mucormycosis (CAM): Living Systematic Review and Meta-Analysis. \textit{Journal of Fungi}. Basel: MDPI, 2021, vol.~7, No~11, p.~1-16. ISSN~2309-608X. Available from: https://dx.doi.org/10.3390/jof7110985.

Detailed Information on Publication Record